Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. (2nd September 2017)

• Record Type: Journal Article
• Authors: Conte, Benedetta; Poggio, Francesca; Del Mastro, Lucia
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 13(2017)
• Page Start: 1357
• Page End: 1362
• Publication Date: 2017-09-02
• Subjects: Gonadotropin-releasing hormones analogs -- ovarian function suppression -- tamoxifen -- aromatase inhibitors -- premenopausal women -- breast cancer; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2017.1363181
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : The role of ovarian function suppression (OFS) through luteinizing hormone-releasing hormone agonists (LHRHa) in addition to tamoxifen has been questioned until recently. In 2015, two large clinical trials led to a paradigm shift in the adjuvant endocrine treatment of premenopausal women, introducing the use of LHRHa plus tamoxifen (or aromatase inhibitor, AI) into current clinical practice. Areas covered : The present review aims to provide an in-depth overview of the role of LHRHa+tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer (HR+BC). Expert opinion : The addition of LHRHa to endocrine treatment (either tamoxifen or AI) is effective in premenopausal women who are at high risk of relapse. To date, no clear recommendations are available for the choice between LHRHa+tamoxifen and LHRH+AI. Although recent data showed better DFS with LHRHa+AI, other issues should be considered: 1) approximately 20 out of 100 women do not reach complete OFS with LHRHa+AI; 2) there is no extended endocrine therapy option that can be applied to women who received 5 years of LHRHa+AI and remained premenopausal at the end of the fifth year. Long-term results of the SOFT-TEXT study are needed to establish if LHRHa+AI is superior to LHRHa+tamoxifen.